Aby J. Mathew, Biolife Solutions EVP, sells $13926 in shares

Aby J. Mathew, Executive Vice President and Chief Scientific Officer at Biolife Solutions INC (NASDAQ:BLFS), a $1.33 billion market cap company with a GREAT financial health score according to InvestingPro, sold 509 shares of common stock on October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $27.36, for a total transaction value of $13,926, near the stock’s 52-week high of $29.55.

Following the transaction, Mathew directly owns 350912 shares of Biolife Solutions INC.

The sale was executed under a Rule 10b5-1 trading plan, adopted on January 3, 2023, to cover tax obligations related to the vesting of restricted stock.

In other recent news, BioLife Solutions reported its second-quarter 2025 earnings, revealing a notable revenue increase to $25.42 million, marking a 29% year-over-year growth. This revenue exceeded analysts’ expectations, though the company posted a net loss of $15.8 million, or $0.33 per share, which was larger than anticipated due to a significant in-process R&D expense. H.C. Wainwright responded by raising its price target on BioLife Solutions to $32 from $30, maintaining a Buy rating on the stock. KeyBanc also reiterated its Overweight rating, highlighting the potential for BioLife Solutions to achieve a 2030 revenue target exceeding $250 million. Additionally, BioLife Solutions announced the sale of its cold chain logistics subsidiary, SAVSU Cleo Technologies, to Peli BioThermal for $25.5 million in cash. The company also held its 2025 annual meeting, where shareholders re-elected the board, approved executive pay, and ratified the appointment of Grant Thornton LLP as the independent auditor. These recent developments reflect BioLife Solutions’ strategic moves and ongoing growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.